The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Pyxis Oncology Inc. shares valued at $4,999,999 were purchased by PFIZER INC on Mar 17. At $2.76 per share, PFIZER INC acquired 1,811,594 shares. The insider’s holdings grew to 5,952,263 shares worth approximately $19.88 million following the completion of this transaction.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Analyzing PYXS Stock Performance
On Wednesday, Pyxis Oncology Inc. [NASDAQ: PYXS] plunged -10.46% to $3.34. The stock’s lowest price that day was $3.12, but it reached a high of $3.54 in the same session. During the last five days, there has been a drop of approximately -9.97%. Over the course of the year, Pyxis Oncology Inc. shares have jumped approximately 149.25%. Shares of the company reached a 52-week high of $6.92 on 03/30/23 and a 52-week low of $1.34 on 01/03/23. A 50-day SMA is recorded $3.24, while a 200-day SMA reached $2.19. Nevertheless, trading volume fell to 0.93 million shares from 0.47 million shares the previous day.
Support And Resistance Levels for Pyxis Oncology Inc. (PYXS)
According to the 24-hour chart, there is a support level at 3.13, which, if violated, would cause prices to drop to 2.91. In the upper region, resistance lies at 3.55. The next price resistance is at 3.75. RSI (Relative Strength Index) is 50.71 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.20, which suggests the price will decrease in the coming days. Percent R is at 53.33%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Pyxis Oncology Inc. subject to short interest?
Stocks of Pyxis Oncology Inc. saw a sharp steep in short interest on Apr 27, 2023 dropping by -1.25 million shares to 3.6 million. Data from Yahoo Finance shows that the short interest on Mar 30, 2023 was 4.85 million shares. A decline of -34.72% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.43 of the overall float, the days-to-cover ratio (short ratio) decline to 0.43.
Which companies own the most shares of Pyxis Oncology Inc. (PYXS)?
According to Laurion Capital Management LP filings, the company currently owns 3,170,803 shares, which is about 8.57% of the total PYXS shares outstanding. With the completion of the sale transaction, Tang Capital Management LLC’s stake is now worth $7,320,903. The Vanguard Group, Inc. acquire a 15.87% interest valued at $3.12 million while Tekla Capital Management LLC 0 stake. In its current portfolio, Point72 Asset Management LP holds 254,247 shares valued at $0.75 million.
In terms of Pyxis Oncology Inc. share price expectations, FactSet research, analysts set an average price target of $10.00 in the next 12 months, up nearly 194.91% from the previous closing price of $3.73. Analysts anticipate Pyxis Oncology Inc. stock to reach $14.00 by 2023, with the lowest price target being $4.00. In spite of this, 5 analysts ranked Pyxis Oncology Inc. stock as a Buy at the end of 2023.